ARS Pharmaceuticals (SPRY) News Today $14.46 +0.30 (+2.12%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$14.46 0.00 (0.00%) As of 05/2/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period ARS Pharmaceuticals Partners with ALK for Neffy PromotionMay 3 at 8:08 PM | investing.comARS Pharmaceuticals (SPRY) Expected to Announce Quarterly Earnings on ThursdayARS Pharmaceuticals (NASDAQ:SPRY) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-ars-pharmaceuticals-inc-stock/)May 3 at 6:05 AM | marketbeat.comARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffyMay 3 at 4:18 AM | msn.comARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. PediatriciansMay 2 at 8:00 AM | globenewswire.comTower Research Capital LLC TRC Has $481,000 Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Tower Research Capital LLC TRC lifted its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 958.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 45,576 shares of the company's sMay 2 at 4:15 AM | marketbeat.comARS Pharmaceuticals Has A Blockbuster CandidateApril 30, 2025 | seekingalpha.comBrokerages Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Target Price at $31.00April 30, 2025 | americanbankingnews.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Recommendation of "Buy" from AnalystsShares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) have been given an average recommendation of "Buy" by the six analysts that are presently covering the firm, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating and one has issued a strong buy raApril 28, 2025 | marketbeat.comRaymond James Financial Inc. Invests $6.58 Million in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Raymond James Financial Inc. purchased a new position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 623,281 shares of the company's stock, valued at approximately $6,576,0April 26, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by Trexquant Investment LPTrexquant Investment LP trimmed its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 33.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 56,563 shares of the company's stock after selling 28,7April 15, 2025 | marketbeat.comExodusPoint Capital Management LP Buys Shares of 24,628 ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)ExodusPoint Capital Management LP bought a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 24,628 shares of the company's stock, vApril 15, 2025 | marketbeat.comVanguard Group Inc. Raises Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Vanguard Group Inc. grew its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 3.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,464,952 shares of the company's stock after purchasing an additiApril 15, 2025 | marketbeat.comLaura Shawver Sells 50,002 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) StockARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) Director Laura Shawver sold 50,002 shares of the stock in a transaction that occurred on Monday, April 7th. The shares were sold at an average price of $12.30, for a total transaction of $615,024.60. Following the completion of the sale, the director now owns 210,346 shares in the company, valued at $2,587,255.80. This represents a 19.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.April 10, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver Sells 50,002 SharesApril 9, 2025 | insidertrades.comSei Investments Co. Invests $1.14 Million in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Sei Investments Co. purchased a new stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 108,273 shares of the company's stock, valued at approximately $1,14April 9, 2025 | marketbeat.comFranklin Resources Inc. Decreases Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Franklin Resources Inc. decreased its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 30.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,976,412 shares of the company's stock after selling 860,840 shares duriApril 8, 2025 | marketbeat.comAlliancebernstein L.P. Has $40.94 Million Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Alliancebernstein L.P. raised its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 5,168.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,880,734 shares of the company's stock after buying an additionalApril 7, 2025 | marketbeat.comARS Pharmaceuticals (SPRY): Among Unstoppable Stocks That Could Double Your MoneyApril 6, 2025 | msn.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 4.9% - Should You Buy?ARS Pharmaceuticals (NASDAQ:SPRY) Trading Up 4.9% - What's Next?April 4, 2025 | marketbeat.comAssuredPartners Investment Advisors LLC Takes $312,000 Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)AssuredPartners Investment Advisors LLC bought a new position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 29,611 shares of the company's stock, valued at approximately $312,000. Several other hMarch 30, 2025 | marketbeat.comSPRY FY2025 EPS Forecast Reduced by Cantor FitzgeraldARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for ARS Pharmaceuticals in a research report issued on Monday, March 24th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the companyMarch 27, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This YearMarch 26, 2025 | finance.yahoo.comRaymond James Financial Inc. Makes New $6.58 Million Investment in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Raymond James Financial Inc. purchased a new stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 623,281 shares of the company's stock, valued at approxMarch 24, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for SPRY FY2028 Earnings?ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Investment analysts at Leerink Partnrs lowered their FY2028 EPS estimates for ARS Pharmaceuticals in a research note issued on Thursday, March 20th. Leerink Partnrs analyst R. Ruiz now expects that the company will post earnings of $1.57 perMarch 24, 2025 | marketbeat.comQ1 EPS Estimate for ARS Pharmaceuticals Reduced by AnalystARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Equities research analysts at William Blair reduced their Q1 2025 earnings estimates for shares of ARS Pharmaceuticals in a research report issued on Thursday, March 20th. William Blair analyst L. Hanbury-Brown now anticipates that the compaMarch 24, 2025 | marketbeat.comInsider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells 10,000 Shares of StockARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) insider Eric Karas sold 10,000 shares of the firm's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $14.00, for a total value of $140,000.00. Following the transaction, the insider now directly owns 7,696 shares in the company, valued at approximately $107,744. This represents a 56.51 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.March 22, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 11.5% - Here's What HappenedARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 11.5% - Here's What HappenedMarch 22, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q4 2024 Earnings Call TranscriptMarch 22, 2025 | insidermonkey.comScotiabank Sticks to Their Buy Rating for ARS Pharmaceuticals (SPRY)March 22, 2025 | markets.businessinsider.comARS Pharmaceuticals’ Earnings Call Highlights Growth and ChallengesMarch 22, 2025 | msn.comARS Pharmaceuticals reports FY24 EPS 8c, consensus (56c)March 21, 2025 | markets.businessinsider.comARS Pharmaceuticals expects cash to fund operations for at least next 3 yearsMarch 21, 2025 | markets.businessinsider.comARS Pharmaceuticals (NASDAQ:SPRY) Posts Earnings Results, Beats Estimates By $0.61 EPSARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) released its earnings results on Thursday. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.61.March 21, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up on Better-Than-Expected EarningsARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up Following Earnings BeatMarch 21, 2025 | marketbeat.comARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges AwaitMarch 20, 2025 | seekingalpha.comARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Conference Call TranscriptMarch 20, 2025 | seekingalpha.comARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 20, 2025 | finanznachrichten.deARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why.March 20, 2025 | investors.comARS Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call PresentationMarch 20, 2025 | seekingalpha.comARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 20, 2025 | globenewswire.comRoyce & Associates LP Acquires 238,158 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Royce & Associates LP raised its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 34.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 929,613 shares of the company's stockMarch 19, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Trading 5.8% Higher - Here's WhyARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 5.8% - Still a Buy?March 13, 2025 | marketbeat.comARS Pharmaceuticals (SPRY) to Release Quarterly Earnings on ThursdayARS Pharmaceuticals (NASDAQ:SPRY) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=672158)March 13, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver Sells 49,600 SharesARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) Director Laura Shawver sold 49,600 shares of the firm's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $11.21, for a total transaction of $556,016.00. Following the completion of the sale, the director now directly owns 210,346 shares of the company's stock, valued at approximately $2,357,978.66. This represents a 19.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.March 8, 2025 | marketbeat.comScotiabank Initiates Coverage of ARS Pharmaceuticals (SPRY) with Sector Outperform RecommendationMarch 8, 2025 | msn.comScotiabank Begins Coverage on ARS Pharmaceuticals (NASDAQ:SPRY)Scotiabank assumed coverage on ARS Pharmaceuticals in a research note on Friday. They set a "sector outperform" rating and a $30.00 price target for the company.March 8, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Recommendation of "Buy" by BrokeragesShares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) have earned an average rating of "Buy" from the seven analysts that are covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recomMarch 8, 2025 | marketbeat.comARS Pharma : FDA Approves Neffy 1 Mg For Type I Allergic Reactions In Pediatric PatientsMarch 7, 2025 | nasdaq.comARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 5.5% - What's Next?ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 5.5% - Should You Buy?March 7, 2025 | marketbeat.comARS Pharmaceuticals initiated with an Outperform at ScotiabankMarch 7, 2025 | markets.businessinsider.com Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Email Address SPRY Media Mentions By Week SPRY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SPRY News Sentiment▼0.830.73▲Average Medical News Sentiment SPRY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SPRY Articles This Week▼85▲SPRY Articles Average Week Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NUVL News Today AXSM News Today GRFS News Today KRYS News Today CYTK News Today ELAN News Today PCVX News Today RYTM News Today PTCT News Today RNA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SPRY) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SPRY Stock Free SPRY Stock Alerts